Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis.
Jérôme Avouac, Barbara G Fürnrohr, Michal Tomcik...
https://pubmed.ncbi.nlm.nih.gov/21360510/Actively Recruiting
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-11-20
74
Participants Needed
46
Research Sites
N/A
Total Duration
Systemic sclerosis SSc is a rare autoimmune disease that causes skin thickening and can affect internal organs, leading to serious health issues. This research evaluates the safety and effectiveness of itacitinib, a drug targeting specific pathways involved in SSc, particularly the JAK-STAT pathway linked to fibrosis and inflammation. The study focuses on adults with diffuse SSc, a severe form with significant skin and organ involvement. Participants are randomly assigned to receive either 200 mg of oral itacitinib daily or a matching placebo for 360 days. The study is a phase II, randomized, controlled trial with quadruple masking to compare outcomes between these two groups. The trial assesses treatment effects on skin thickening and disease activity over the course of one year. During the study, participants undergo regular assessments including skin scoring modified Rodnan skin score, disease activity evaluations, and quality of life questionnaires at multiple time points up to 360 days. Safety is monitored through adverse event tracking and laboratory tests. The main outcome measured is the change in skin thickness after 360 days of treatment, helping researchers understand the potential impact of itacitinib on systemic sclerosis.
CONDITIONS
Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis
B
Benjamin Chaigne, MD
A
Adèle BELLINO
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Assistance Publique - Hôpitaux de Paris
Lead Sponsor
URC-CIC Paris Descartes Necker Cochin
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 360 days
Participants receive oral Itacitinib or placebo daily as part of the study treatment.
Regular visits for assessments during treatment up to 360 days
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jérôme Avouac, Barbara G Fürnrohr, Michal Tomcik...
https://pubmed.ncbi.nlm.nih.gov/21360510/Yang Xu, Wenling Wang, Yanli Tian...
https://pubmed.ncbi.nlm.nih.gov/26712637/Youngqing Wang, Pan-Sheng Fan, Bashar Kahaleh
https://pubmed.ncbi.nlm.nih.gov/16802366/Joel M Kremer, Bradley J Bloom, Ferdinand C Breedveld...
https://pubmed.ncbi.nlm.nih.gov/19565475/Yun Zhang, Ruifang Liang, Chih-Wei Chen...
https://pubmed.ncbi.nlm.nih.gov/28478401/K Migita, Y Izumi, T Torigoshi...
https://pubmed.ncbi.nlm.nih.gov/23968543/Jörg H W Distler, Carol Feghali-Bostwick, Alina Soare...
https://pubmed.ncbi.nlm.nih.gov/27636741/C Landi, E Bargagli, L Bianchi...
https://pubmed.ncbi.nlm.nih.gov/23528693/Cristiana Almeida, Isabel Almeida, Carlos Vasconcelos
https://pubmed.ncbi.nlm.nih.gov/26212726/Jordan S Fridman, Peggy A Scherle, Robert Collins...
https://pubmed.ncbi.nlm.nih.gov/21677670/Assistance Publique - Hôpitaux de Paris
Lead Sponsor
URC-CIC Paris Descartes Necker Cochin
Collaborating Sponsor